Search results
FDA panel rejects MDMA-assisted therapies for PTSD despite high hopes from veterans
Fox News· 2 days agoA U.S. Food and Drug Administration (FDA) panel rejected MDMA-based treatments for post-traumatic...
Supreme Court Upholds FDA Regulation on Popular Abortion Drug Mifepristone
WFMZ Eastern Pennsylvania and Western New Jersey· 1 day agoSupreme Court Upholds , FDA Regulation on Popular , Abortion Drug Mifepristone. On June 13, the...
Why FDA Panel Rejected MDMA Therapy—And What’s Next For Psychedelic Medicine
Forbes· 2 days agoThe FDA has previously acknowledged its therapeutic potential, granting a new drug application,...
FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment
Yahoo Finance· 4 days agoThe monoclonal antibody drug, delivered through an IV monthly for up to 18 months, would be the...
Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
Zacks via Yahoo Finance· 4 days agoBiogen expects sales of Leqembi to start growing from 2024 with signs of acceleration seen in the...
FDA Advisers Like Lilly’s Alzheimer’s Drug. It’s Good News for Biogen.
Barrons.com· 3 days agoAdministering these anti-amyloid antibodies is difficult, and involves a robust infrastructure for...
Leo’s single-dose autoinjector secures FDA approval for atopic dermatitis
Pharmaceutical Technology via Yahoo Finance· 1 day agoAdbry targets interleukin-13 (IL-13), a cytokine that drives inflammatory processes...filled...
Alzheimer’s drug that can slow disease gets backing from FDA advisers - The Boston Globe
The Boston Globe· 4 days agoThe FDA approved a similar infused drug, Leqembi, from Biogen and Japanese drugmaker Eisai, last year. In a separate vote, the FDA advisers ...
Eli Lilly's Alzheimer's Drug Gains Unanimous FDA Panel Backing
Verywell Health via Yahoo News· 3 days agoAn FDA advisory panel endorsed donanemab, Eli Lilly’s monoclonal antibody drug designed to slow the...
FDA panel endorses approval of Alzheimer’s drug shown to slow progression of disease
WSB Radio· 3 days agoIf approved by the FDA, Eli Lilly’s Alzheimer’s drug donanemab, would become the second Alzheimer’s...